Blog
Apr 28, 2026, 7:16 AM
PASADENA, Calif., April 28, 2026– AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company $7.5 million in grant funding to support the advancement of its lead clinical candidate, AS-241, toward first‑in‑human testing.
Apr 16, 2026, 5:15 PM
PASADENA, Calif., April 16, 2026 – AcuraStem, a patient‑based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, today announced the establishment of its European subsidiary, AcuraStem P2 Ltd, based in Nicosia, Cyprus.